Generic Times Product News
Finasteride Tablets USP, 5 mg
Marketed by:Mylan Pharmaceuticals Inc(Pittsburgh, Pa)
Compared to:Proscar Tablets(Merck & Co Inc)
Indication:December 19, 2006?Mylan Laboratories Incannounced that Mylan Pharmaceuticals Inc wasgranted final FDA approval for its abbreviated newdrug application for finasteride tablets USP, 5 mg.These tablets are indicted for the treatment ofsymptomatic benign prostatic hyperplasia in menwith an enlarged prostate to improve symptomsand reduce the risk of the need for surgery, includingtransurethral resection of the prostate andprostatectomy.
Dosage Form:Tablets: 5 mg
For More Information:www.mylan.com
Isosorbide Dinitrate 30-mg Tablet
Marketed by:West-ward Pharmaceutical Corp(Eatontown, NJ)
Compared to:Isordil (Wyeth Laboratories)
Indication:February 22, 2006?West-wardPharmaceutical Corp launchedIsosorbide Dinitrate 30-mg tablets.These tablets are indicated for theprevention of angina pectoris due to coronaryartery disease. The onset of action of immediate-releaseoral isosorbide dinitrate is not sufficientlyrapid for the product to be useful in aborting anacute anginal episode.
Dosage Form:Tablets (oral): 30 mg; also available are 2.5-and 5-mg sublingual tablets, and 5-, 10-, and 20-mg oraltablets
For More Information:800-631-2174
Simvastatin Tablets, 5, 10, 20, and 40 mg
Marketed by:RanbaxyPharmaceuticals Inc,a wholly owned subsidiaryof RanbaxyLaboratories Ltd(Guragon, India)
Compared to:Zocor Tablets (Merck Research Laboratories)
Indication:December 21, 2006?Ranbaxy Laboratories Ltdannounced that it received approval from the FDAto manufacture and market Simvastatin Tablets USP,5, 10, 20, and 40 mg in the United States.Simvastatin tablets are indicated in the treatment ofpatients with coronary heart disease (CHD) or athigh risk of CHD or for reductions in risk of CHDmortality and cardiovascular events; patients withhypercholesterolemia requiring modifications of lipidprofiles; and adolescent patients with heterozygousfamilial hypercholesterolemia. A simvastatin regimencan be started simultaneously with diet.
Dosage Form:Tablets: 5, 10, 20, and 40 mg
For More Information:www.ranbaxy.com
Marketed by:TevaPharmaceuticals(North Wales, Pa)
Compared to:Mavik (Abbott GMBH and Co)
Indication:February 7, 2007?Teva Pharmaceuticalsannounced the introduction and availability ofTrandolapril Tablets. These tablets are indicated forthe treatment of hypertension. They may be usedalone or in combination with other antihypertensivemedications such as hydrochlorothiazide.Trandolapril is the ethyl ester prodrug of a nonsulfhydrylangiotensin-converting enzyme inhibitor,trandolaprilat.
Dosage Form:Tablets: 1, 2, and 4 mg
For More Information:www.tevausa.com